3.13 USD
+0.34 (+12.19%)
Overall MTBC gets a fundamental rating of 3 out of 10. We evaluated MTBC against 35 industry peers in the Health Care Technology industry. MTBC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MTBC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MTBC has reported negative net income.
In the past year MTBC had a positive cash flow from operations.
1.2 Ratios
The profitability ratios for MTBC are negative, so there is not much use analyzing them.
MTBC has a better Return On Invested Capital (4.81%) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | 4.81% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of MTBC (3.77%) is better than 77.78% of its industry peers.
The Gross Margin of MTBC (38.04%) is worse than 62.22% of its industry peers.
In the last couple of years the Gross Margin of MTBC has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.77% | ||
| PM (TTM) | N/A | ||
| GM | 38.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5Y-3.59%
2. Health
2.1 Basic Checks
MTBC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MTBC has more shares outstanding
MTBC has a worse debt/assets ratio than last year.
2.2 Solvency
MTBC has an Altman-Z score of 2.01. This is not the best score and indicates that MTBC is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.01, MTBC is in the better half of the industry, outperforming 62.22% of the companies in the same industry.
The Debt to FCF ratio of MTBC is 0.06, which is an excellent value as it means it would take MTBC, only 0.06 years of fcf income to pay off all of its debts.
MTBC has a better Debt to FCF ratio (0.06) than 86.67% of its industry peers.
MTBC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, MTBC is in the better half of the industry, outperforming 68.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 2.01 |
ROIC/WACC0.61
WACC7.84%
2.3 Liquidity
A Current Ratio of 1.21 indicates that MTBC should not have too much problems paying its short term obligations.
With a Current ratio value of 1.21, MTBC is not doing good in the industry: 68.89% of the companies in the same industry are doing better.
MTBC has a Quick Ratio of 1.19. This is a normal value and indicates that MTBC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.19, MTBC is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 56.73% over the past year.
The Revenue has been growing slightly by 7.14% in the past year.
The Revenue has been growing by 41.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y40.35%
Revenue growth 5Y41.63%
Sales Q2Q%-11.96%
3.2 Future
Based on estimates for the next years, MTBC will show a small growth in Earnings Per Share. The EPS will grow by 6.25% on average per year.
Based on estimates for the next years, MTBC will show a small growth in Revenue. The Revenue will grow by 2.57% on average per year.
EPS Next Y13.69%
EPS Next 2Y7.89%
EPS Next 3Y16.8%
EPS Next 5Y6.25%
Revenue Next Year0.64%
Revenue Next 2Y1.19%
Revenue Next 3Y3.72%
Revenue Next 5Y2.57%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MTBC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTBC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MTBC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MTBC indicates a rather cheap valuation: MTBC is cheaper than 97.78% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.4 | ||
| EV/EBITDA | 2.55 |
4.3 Compensation for Growth
MTBC's earnings are expected to grow with 16.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.89%
EPS Next 3Y16.8%
5. Dividend
5.1 Amount
MTBC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MTBC (1/9/2023, 8:23:58 PM)
3.13
+0.34 (+12.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners11.55%
Inst Owner Change7.54%
Ins Owners0.89%
Ins Owner Change0%
Market Cap47.61M
Revenue(TTM)143.75M
Net Income(TTM)-6.85M
Analysts83.64
Price Target9.69 (209.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-220.54%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.24%
Min EPS beat(2)4.61%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)48.06%
Min EPS beat(4)4.61%
Max EPS beat(4)94.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.73%
Min Revenue beat(2)-3.14%
Max Revenue beat(2)-2.32%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)2.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.54%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | 5.4 | ||
| P/OCF | 2.24 | ||
| P/B | 0.46 | ||
| P/tB | 4.01 | ||
| EV/EBITDA | 2.55 |
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)0.58
FCFY18.5%
OCF(TTM)1.4
OCFY44.58%
SpS9.45
BVpS6.76
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | 4.81% | ||
| ROICexc | 4.99% | ||
| ROICexgc | 43.34% | ||
| OM | 3.77% | ||
| PM (TTM) | N/A | ||
| GM | 38.04% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5Y-3.59%
F-Score4
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 103.98% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.01 |
F-Score4
WACC7.84%
ROIC/WACC0.61
Cap/Depr(3y)81.08%
Cap/Depr(5y)58.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y13.69%
EPS Next 2Y7.89%
EPS Next 3Y16.8%
EPS Next 5Y6.25%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y40.35%
Revenue growth 5Y41.63%
Sales Q2Q%-11.96%
Revenue Next Year0.64%
Revenue Next 2Y1.19%
Revenue Next 3Y3.72%
Revenue Next 5Y2.57%
EBIT growth 1Y261.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1308.1%
EBIT Next 3Y177.57%
EBIT Next 5Y93.09%
FCF growth 1Y213.67%
FCF growth 3Y-21.74%
FCF growth 5YN/A
OCF growth 1Y1553.9%
OCF growth 3Y25.1%
OCF growth 5YN/A
CARECLOUD INC / MTBC FAQ
Can you provide the ChartMill fundamental rating for CARECLOUD INC?
ChartMill assigns a fundamental rating of 3 / 10 to MTBC.
What is the valuation status of CARECLOUD INC (MTBC) stock?
ChartMill assigns a valuation rating of 3 / 10 to CARECLOUD INC (MTBC). This can be considered as Overvalued.
Can you provide the profitability details for CARECLOUD INC?
CARECLOUD INC (MTBC) has a profitability rating of 1 / 10.
How financially healthy is CARECLOUD INC?
The financial health rating of CARECLOUD INC (MTBC) is 4 / 10.
What is the earnings growth outlook for CARECLOUD INC?
The Earnings per Share (EPS) of CARECLOUD INC (MTBC) is expected to grow by 13.69% in the next year.